Condition: Neuromyelitis Optica Spectrum Disorder · NMOSD · AQP4+ NMOSD · Sponsor: Alexion Pharmaceuticals, Inc.
Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Washington D.C., District of Columbia, United States | Recruiting |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Clinical Trial Site | Chapel Hill, North Carolina, United States | Not Yet Recruiting |
| Clinical Trial Site | Columbus, Ohio, United States | Recruiting |
| Clinical Trial Site | Plano, Texas, United States | Recruiting |
| Clinical Trial Site | Milwaukee, Wisconsin, United States | Recruiting |
| Clinical Trial Site | Buenos Aires, Argentina | Recruiting |
| Clinical Trial Site | Buenos Aires, Argentina | Not Yet Recruiting |
| Clinical Trial Site | Buenos Aires, Argentina | Recruiting |
| Clinical Trial Site | Buenos Aires, Argentina | Recruiting |
| Clinical Trial Site | Burnaby, British Columbia, Canada | Recruiting |
| Clinical Trial Site | Beijing, China | Not Yet Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05966467